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Abstract
Background: Persons affected by neurofibromatosis type 1 (NF1) have a decreased survival, yet information on
NF1-associated mortality is limited.
Methods/Aim: The National Mortality Database and individual Multiple-Causes-of-Death records were used to
estimate NF1-associated mortality in Italy in the period 1995-2006, to compare the distribution of age at death (as
a proxy of survival) to that of the general population and to evaluate the relation between NF1 and other medical
conditions by determining whether the distribution of underlying causes of NF1-associated deaths differs from that
of general population.
Results: Of the nearly 6.75 million deaths in the study period, 632 had a diagnosis of NF1, yet for nearly three-
fourths of them the underlying cause was not coded as neurofibromatosis. The age distribution showed that NF1-
associated deaths also occurred among the elderly, though mortality in early ages was high. The mean age for
NF1-associated death was approximately 20 years lower than that for the general population. The gender
differential may suggest that women are affected by more severe NF1-related complications, or they may simply
reflect a greater tendency for NF1 to be reported on the death certificates of young women. Regarding the
relation with other medical conditions, we found an excess, as the underlying cause of death, for malignant
neoplasm of connective and other soft tissue and brain, but not for other sites. We also found an excess for
obstructive chronic bronchitis and musculoskeletal system diseases among elderly persons.
Conclusion: This is the first nationally representative population-based study on NF1-associated mortality in Italy. It
stresses the importance of the Multiple-Causes-of-Death Database in providing a more complete picture of
mortality for conditions that are frequently not recorded as the underlying cause of death, or to study complex
chronic diseases or diseases that have no specific International Classification of Diseases code, such as NF1. It also
highlights the usefulness of already available data when a surveillance system is not fully operational.
Background
Neurofibromatosis type 1 (NF1) is an autosomal domi-
nant disorder which affects 1 in 2500-3000 live births
[1,2]. It is a progressive multisystem disorder character-
ized by a wide variety of clinical signs and symptoms, a
totally unpredictable evolution, and an increased risk of
malignancy. The gene responsible for NF1 encodes
neurofibromin, a protein which acts as a tumor suppres-
sor, the loss of which leads to an increased risk of devel-
oping tumors. The hallmark feature of NF1 is benign
neurofibromas (a peripheral nerve sheath tumor); the
other NF1-defining manifestations consist of cafè au lait
patches, skin-fold freckling, iris Lisch nodules, optic
pathway glioma, and bony dysplasia [3]. NF1 can also
result in serious complications which affect diverse body
systems and which are responsible for the deaths related
to NF1; these include disfigurement, evolving scoliosis,
cognitive or neurological impairment, vasculopathy, and
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eral and central nerve tissue [4-11].
Although persons with NF1 have a decreased survival,
information on NF1-associated mortality is limited.
Only one nationally representative population-based
study on NF1 mortality based on death certificates has
been published [12], and the information on the causes
of death among persons with NF1 mainly derives from
case series. Moreover, given that NF1 has a variety of
clinical manifestations and complications of varying
degrees of severity, it may not be recorded as the official
cause of death. An additional problem is that no specific
code exists for NF1 in the International Classification of
Diseases (ICD), so that it is not possible to distinguish it
from other types of neurofibromatosis, such as neurofi-
bromatosis type 2 (NF2). The importance of this distinc-
tion lies in the fact that NF1 and NF2 are clinically and
genetically different, generally with different symptoms
and requiring distinct medical management; nonetheless,
they are often confused for one another by clinicians.
Although NF2 is more aggressive, NF1 is numerically
more important, in that its incidence is about 10 times
greater than that of NF2 [13].
The objective of this study was to estimate NF1-
associated mortality in Italy, in particular, the number
of NF1-associated deaths in the past 12 years; we also
compared the distribution of age at death to that of
the general population, so as to have an indication of
survival, and explored the relation between NF1 and
other medical conditions.
Methods
Data sources
Two data sources were used: the National Mortality
Database, and individual Multiple-Causes-of-Death
records, provided by Italy’s National Institute of Statis-
tics (ISTAT). The National Mortality Database contains
the underlying cause of death for all persons who died
from 1970 to 2006 (most recent data available), which is
coded by ISTAT. Until 2002, the 9
th Revision of the
ICD (ICD-9) was used; since then, ICD-10 has been
used; however, in 2004 and 2005, the underlying cause
was not codified. A single code is used for all types
of neurofibromatoses: 237.7 in ICD-9 and Q85.0 in
ICD-10.
The Multiple-Causes-of-Death records contain all
causes and other important conditions as reported by
the certifying physician on the death certificate, they are
available for the period 1995-2006 and cover the entire
country, with the exception of residents in the provinces
of Trento and Bolzano and infants (less than one year
of age); for infants, Multiple-Causes-of-Death records
have been available since 2003. All of the conditions
and diseases reported on the medical part of the death
certificate are entered in the database by data-entry spe-
cialists; this step is supported by a dictionary of medical
terms which provides assistance in case of incorrect
entries.
All deaths in 1995-2003 and 2006 that were coded as
237.7 or Q85.0 were selected from the National Mortal-
ity Database; to obtain information on all of the diag-
noses for these individuals, these deaths were linked to
the Multiple-Causes-of-Death records, using the anon-
ymous individual identification code used by both sys-
tems. Moreover, all Multiple-Causes-of-Death records
with neurofibromatosis reported anywhere on the death
certificate (as underlying or other cause) were selected
by searching for the term “neurofibromatosis” or any
synonym, acronym or short form of “neurofibromatosis”
or “Von Recklinghausen” disease; the search was
expanded to include symptoms of NF1 (complete term,
synonym, or acronym), according to published diagnos-
tic criteria [3].
We then excluded all Multiple-Causes-of-Death
records with the following:
￿ the term “neurofibroma” without any other indica-
tion of neurofibromatosis (16 cases)
￿ an evident diagnosis of Neurofibromatosis type 2
(NF2) (17 cases)
￿ a diagnosis of neurofibromatosis (type not specified)
with acoustic neurinoma or meningyoma (or synonyms),
which are more likely to be associated with NF2 (6
cases).
We also included the three deaths in the provinces of
Trento and Bolzano (all three from Bolzano) for which
the underlying cause was coded as 237.7 or Q85.0 (not
included in the Multiple-Causes-of-Death database).
With the exception of these three deaths, all deaths
coded as 237.7 or Q85.0 in the National Mortality Data-
base were present in the Multiple-Causes-of-Death
records. Similarly, all deaths selected from the Multiple-
Causes-of-Death database with a diagnosis of NF1 were
present in the National Mortality Database, although for
the 101 deaths in the period 2004-2005, only demo-
g r a p h i cd a t aw e r ea v a i l a b l ei nt h eN a t i o n a lM o r t a l i t y
Database whereas the underlying cause was not coded.
Table 1 shows the diagnosis written out on death cer-
tificates of the individuals included in the analysis.
Statistical analyses
We calculated the mean annual NF1-associated mortal-
i t yb ya g e ,u s i n gt h eI t a l i a np o p u l a t i o na t1J a n u a r y
2001 [14] as a proxy of the average annual person-years
in 1995-2006. We also estimated the mean annual NF1-
associated mortality for men and women, adjusted by
age and sex, using direct method and the Italian popula-
tion at 1 January 2001 as standard population. To evalu-
ate gender differences, we calculated the standardized
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rates, with relative 95% confidence intervals (CI) [15].
To approximate the survival of persons with NF1, we
compared the age distribution of NF1-associated deaths
with the age distribution of persons who died from all
causes in the same period.
For NF1-associated deaths and persons who died from
all causes, the mean and median age at death, and the
5th, 25th, 75th, 95th percentiles of age distribution were
calculated overall, by gender, and, to investigate tem-
poral differences, for the periods 1995-2000 and 2001-
2006. Differences in mean age at death, and relative 95%
CI, between NF1-associated deaths and deaths from all
causes were calculated.
To investigate whether or not the effect of NF1-
associated mortality was restricted to younger patients,
the analyses were repeated for persons who were 40
years old or older.
Non-parametric methods (U Mann-Whitney test,
Median test) were used to test the gender and temporal
differences in mean ages at death of NF1-associated
deaths, because the age distribution of these cases was
skewed and bi-modal (p < 0.001: Kolmogorov-Smirnov
test for normality distribution). Student-t test was used
to evaluate gender and temporal differences in mean age
at death among the general population (deaths from all
causes). The analyses were performed using SPSS soft-
ware (version 17).
To investigate the potential association between NF1
and other conditions, we determined whether the distri-
bution of the underlying causes of NF1-associated
deaths differed from that of the general population by
calculating the Proportionate Mortality Ratio (PMR).
For each condition (or group of conditions) reported as
underlying cause of death for NF1-associated deaths, the
PMR was calculated as the ratio of observed deaths to
expected deaths; the expected deaths were based on the
proportion of deaths due to the given condition among
the same-age general population of persons who died in
the same calendar period. An excess of a given condi-
tion among deceased persons with NF1 is indicated by a
PMR >1, whereas a deficit is indicated by a PMR <1.
The 95% CI of PMRs were calculated using the Byar’s
formula as an approximation of the exact Poisson test
[16].
Results
NF1-associated deaths
Of the nearly 6 753 000 deaths in 1995-2006, 632 had a
diagnosis of NF1 on the death certificate (herein defined
as “NF1-associated deaths”); of these, 150 had neurofi-
bromatosis as the underlying cause of death (ICD-9:
237.7; ICD-10: Q85.0).
The mean annual frequency of NF1-associated deaths
was 1/10 685 deaths, and the mean annual NF1-
associated mortality was 0.92 per 1 million population.
The age-sex-adjusted mortality was 1.01 for men (95%
CI: 0.62-1.40) and 0.85 for women (95% CI: 0.52-1.17)
(RR = 1.19, 95% CI: 0.69-2.06).
Mortality increased with age, yet premature mortality
was high, and 185 of the 632 deaths identified (30%)
were at ages younger than 40 years (Figure 1). In parti-
cular, age-specific mortality rates increased, reaching a
relative maximum at 40 years; in the successive 10 years
it then decreased, reaching the same levels found among
adolescents; finally, after the age of 50 years, it began to
increase continuously.
The distribution of NF1-associated deaths was more
spread out than that for deaths for all causes (Figure 2).
NF1-associated deaths were, on average, younger than
deaths for all causes, for both men and women. Of the
NF1-associated deaths, 5% occurred among persons
younger than 17 years of age and 25% among persons
younger than 36 years, whereas among the general
population, 5% of deaths occurred among persons
younger than 50 years and 25% among persons younger
than 70 years. The median age of NF1-associated death
was 60 years, compared to 79 years for the general
population; the difference in median age of death was
slightly larger among women, compared to men.
The mean age at death for NF1-associated deaths was
55.5 years, compared to 76.2 years for the general popu-
lation; it was greater among women than among men,
yet the gender difference, although significant, was smal-
ler compared to that of the general population (Table 2).
From 1995-2002 to 2001-2006, there was an increase in
the mean age of NF1-associated deaths, and this
increase was greater than that observed for the general
population.
Table 1 Diagnosis reported on the death certificates of
persons identified as having neurofibromatosis type 1
Alphanumeric string on death certificate No. of
deaths
“Von Recklingausen” disease 344
“Neurofibromatosis” not otherwise specified (without
mention of acoustic Neurinoma and/or Meningyoma)
215
“Diffuse Neurofibromatosis” 33
“Neurofibromatosis Type 1” 24
“Cutaneous Neurofibromatosis” 7
“Visceral or Retroperitoneal Neurofibromatosis” 3
“Cerebral Neurofibromatosis” (not otherwise specified and
without any symptoms)
3
Deaths from National Mortality Database but not present
in Multiple-Causes-of-Death records (deaths from Trento
and Bolzano)
3
Total 632
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and older, the gap in the mean age of death between
NF1-cases and the general population was 10.6 years
(mean age of death of 67.3 years vs. 77.9 years) (Table 2).
Excesses and deficits of underlying causes
The estimated PMR for the major groups of underlying
causes for NF1-associated deaths are shown in Table 3;
the results refer to the 531 deaths that occurred in
1995-2003 and 2006. For approximately 72% of the
NF1-associated deaths, the underlying cause was coded
as a pathology other than neurofibromatosis. Of these
causes, neoplasms (ICD-9 140-239, excluding 237.7;
ICD-10 C00-D48) were the most frequent, accounting
for one third of all NF1-associated deaths.
According to the PMR, with regard to malignant
tumors, a 22-fold excess was found for connective and
other soft tissue (PMR = 22.3, 95% CI: 15.50-30.95), and
a 4-fold excess for brain (PMR = 4.2, 95% CI: 2.69-6.15).
A 20-fold excess was also found for other and unspeci-
fied parts of the nervous system (other than brain)
(PMR = 20.4, 95% CI: 5.50-52.35) and a 4-fold excess
Figure 1 Annual average NF1-associated mortality (per 1,000,000 population) and total number of deaths, by age; 1995-2006.
Figure 2 Median (in box) and 5
th,2 5
th,7 5
th and 95
th percentiles of age at death.
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10.72), though they referred to fewer cases. When
excluding the above malignant neoplasms (neoplasm of
connective and soft tissue, brain, unspecified parts of
the nervous system and ill-defined sites), there was a
significant deficit for malignant neoplasms as a group
(PMR = 0.6, 95% CI: 0.45-0.69). There were also signifi-
cant excesses for benign neoplasms (PMR = 9.2, 95% CI:
3.69-18.99) and neoplasms of uncertain behavior and
unspecified nature (other than neurofibromatosis)
(PMR = 2.9, 95% CI: 1.72-4.72).
O ft h en o n - n e o p l a s t i cd i s e a s e s ,as l i g h te x c e s sw a s
found for those of the respiratory system as a whole,
which can be attributed to the excess found for obstruc-
tive chronic bronchitis (PMR = 2.0, 95% CI: 1.06-3.40).
The estimated PMRs stratified by age are shown in
Table 4. For persons who died before the age of 40 the
PMRs were higher with respect to those for all ages for
malignant neoplasm of connective and soft tissue, brain,
unspecified parts of the nervous system and without
specification of the sites and for benign neoplasms and
neoplasms of uncertain behavior, which resulted in an
increase in PMRs for all neoplasms as a group and
malignant neoplasms as a group (PMR = 2.9, 95% CI:
2.33-3.68 and PMR = 2.8, 95% CI: 2.15-3.51, respec-
tively). By contrast, the PMR for respiratory diseases
was no longer significant. Among persons who died at
40 years of age or older, the PMRs continued to be sig-
nificant only for malignant neoplasm of connective and
soft tissue, benign neoplasms and neoplasms of uncer-
tain behavior and for diseases of the respiratory system;
a significant excess was also found for diseases of the
musculoskeletal system (PMR = 3.6, 95% CI: 1.15-8.34).
Discussion
Of the nearly 6 753 000 deaths in Italy in 1995-2006,
632 had a diagnosis of NF1 on the death certificate, yet
for nearly three-fourths of them the underlying cause
was coded as another pathology.
With regard to age, the bimodal trend in NF1-
associated mortality emphasizes the weight of prema-
ture mortality (i.e., before 40 years of age): mortality
dramatically increased from adolescence to 40 years of
age, with one third (n = 185) of the deaths occurring
before 40 years; after 40 years, the mortality decreased
until 50 years of age and then showed a constant
increase for older ages, with the highest absolute num-
b e ro fd e a t h sa m o n g7 0 - 7 4y e a ro l d s .
Compared to the general population, the mean age of
NF1-associated deaths was approximately 20 years
lower, and it was approximately 10 years lower when
the analysis was restricted to persons 40 years of age
and older, again demonstrating how the effect of NF1-
associated mortality was mainly restricted to younger
Table 2 Mean age at death and Standard Deviation (SD) for NF1-associated deaths and all causes (among the general
population), by gender, calendar period and age class; Italy, 1995-2006
ALL AGES NF1-associated deaths Mean age at death (SD) Differences in mean age at death (95% CI)
NF1 All causes NF1 vs. All causes
Total 632 55.5 (21.8) 76.2 (15.2) 20.7 (19.0 - 22.4)
Men 316 53.3 (21.2) 72.8 (15.6) 19.5 (17.2 - 21.9)
Women 316 57.7 (22.1) 79.5 (14.0) 21.8 (19.4 - 24.3)
Gender difference 4.4 p ≤ 0.004 6.7 p ≤ 0.0001
1995-2000 329 54.4 (22.0) 75.3 (15.5) 20.9 (18.5 - 23.3)
2001-2006 303 56.7 (21.5) 77.0 (14.8) 20.3 (17.9 - 22.7)
Temporal difference 2.4 n.s. 1.8 p ≤ 0.0001
AGES ≥ 40 years NF1-associated deaths Mean age at death (SD) Differences in mean age at death (95% CI)
NF1 All causes NF1 vs. All causes
Total 447 67.3 (12.9) 77.9 (11.9) 10.6 (9.4 - 11.8)
Men 215 65.5 (12.6) 75.0 (11.8) 9.5 (7.8 - 11.2)
Women 232 68.9 (13.0) 80.7 (11.3) 11.8 (10.1 - 13.5)
Gender difference 3.4 p ≤ 0.004 5.7 p ≤ 0.0001
1995-2000 230 66.6 (12.9) 77.2 (11.8) 10.7 (9.0 - 12.3)
2001-2006 217 68.0 (12.9) 78.5 (11.9) 10.5 (8.8 - 12.2)
Temporal difference 1.4 n.s. 1.3 p ≤ 0.0001
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Number PMRs 95% CI
Underlying cause of death (ICD-9 and ICD-10 Codes ) Observ. Expect.
Neurofibromatosis (ICD-9: 237.7; ICD-10: Q85.0) 150 -
Neoplasms, excluding neurofibromatosis (ICD-9: 140-239,
excluding 237.7; ICD-10: C00-D48)
182 175.5 1.0 (0.89 - 1.20)
Malignant neoplasms (ICD-9:140-208; ICD10: C00-C97) 158 169.0 0.9 (0.79 - 1.09)
Lip, oral cavity and pharynx (ICD-9:140-149; ICD10: C00-C14) 1 4.1 0.2 (0.00 - 1.37)
Colorectal (ICD-9:153-154; ICD-10: C18-C21) 9 15.6 0.6 (0.26 - 1.09)
Stomach (ICD-9:151; ICD10: C16) 2 10.9 0.2 (0.02 - 0.66)
Liver and intrahepatic bile ducts (ICD-9:155; ICD10: C22) 1 9.9 0.1 (0.00 - 0.56)
Pancreas (ICD-9:157; ICD10: C25) 5 7.9 0.6 (0.20 - 1.47)
Trachea/bronchus/lung (ICD-9:162; ICD-10: C33-C34) 11 34.3 0.3 (0.16 - 0.57)
Bone and articular cartilage (ICD-9:170; ICD-10: C40-C41) 3 1.3 2.3 (0.45 - 6.59)
Connective and other soft tissue (ICD-9:171; ICD-10: C49) 35 1.6 22.3 (15.50 - 30.95)
Skin (malignant melanoma) (ICD-9:172: ICD-10: C43) 4 2.6 1.5 (0.41 - 3.89)
Breast (ICD-9:174-175; ICD-10: C50) 6 15.2 0.4 (0.14 - 0.86)
Body (or unspecified part) of uterus (ICD-9:179; 182; ICD-10: C54-C55) 1 2.6 0.4 (0.01 - 2.15)
Cervix uteri (ICD-9:180; ICD-10: C53) - - - -
Ovary (ICD-9:183.0; ICD-10: C56) 2 3.5 0.6 (0.06 - 2.04)
Prostate (ICD-9:185; ICD-10: C61) 1 4.2 0.2 (0.00 - 1.31)
Kidney, except pelvis (ICD-9:189.0; ICD-10: C64) 2 3.2 0.6 (0.07 - 2.27)
Bladder (ICD-9:188; ICD-10: C67) 4 3.9 1.0 (0.28 - 2.65)
Brain (ICD-9:191; ICD-10: C71) 25 6.0 4.2 (2.69 - 6.15)
Other and unspecified parts of nervous system (ICD-9:192; ICD-10: C70; C72) 4 0.2 20.4 (5.50 - 52.35)
Other and ill-defined sites (ICD-9:195; ICD-10: C76) 4 1.0 4.2 (1.13 - 10.72)
Neoplasm without specification of site (ICD-9:199; ICD-10: C80) 9 4.6 2.0 (0.89 - 3.72)
Lymphatic and hematopoietic tissue (ICD-9: 200-208; ICD-10: C81-C96) 5 18.3 0.3 (0.09 - 0.64)
Malignant neoplasms (excluding those of connective and soft tissue, brain,
other and unspecified parts of nervous system, or other and ill-defined sites)
90 160.2 0.6 (0.45 - 0.69)
Benign Neoplasms (ICD-9:210-229; ICD-10: D10-D36) 7 0.8 9.2 (3.69 - 18.99)
Neoplasms of uncertain behavior and unspecified nature, excluding neurofibromatosis
(ICD-9: 235-239, excluding 237.7; ICD-10: D37-D48)
17 5.8 2.9 (1.72 - 4.72)
Infectious and parasitic diseases, including AIDS (ICD-9: 1-139, 279.1; ICD-10: A00-B99) 5 17.5 0.3 (0.09 - 0.67)
Endocrine, nutritional and metabolic diseases (ICD-9: 240-278 ICD-10: E00-E90) 9 15.9 0.6 (0.26 - 1.07)
Diabetes mellitus (ICD-9: 250; ICD-10: E10-E14) 2 12.3 0.2 (0.02 - 0.59)
Diseases of the blood and blood-forming organs and certain disorders involving
the immune mechanism, excluding AIDS (ICD-9: 279-289; excluding 279.1; ICD-10: D50-D89)
2 2.6 0.8 (0.09 - 2.78)
Mental disorders (ICD-9: 290-319; ICD-10: F00-F99) 1 10.1 0.1 (0.00 - 0.55)
Diseases of the nervous system and sense organs (ICD-9: 320-389; ICD-10: G00-H95) 10 13.8 0.7 (0.35 - 1.33)
Diseases of the circulatory system (ICD-9: 390-459; ICD-10: I00-I99 ) 101 143.5 0.7 (0.57 - 0.86)
Hypertensive disease (ICD-9: 401-405; ICD-10: I10-I15) 6 9.9 0.6 (0.22 - 1.32)
Ischemic heart disease (ICD-9: 410-414; ICD-10: I20-I25) 23 51.0 0.5 (0.29 - 0.68)
Cerebrovascular disease (ICD-9: 430-438; ICD-10: I60-I69) 31 35.4 0.9 (0.59 - 1.24)
Diseases of the respiratory system (ICD-9: 460-519; ICD-10: J00-J99) 33 21.4 1.5 (1.06 - 2.17)
Obstructive chronic bronchitis (ICD-9: 491.2; ICD-10: J448) 13 6.5 2.0 (1.06 - 3.40)
Diseases of the digestive system (ICD-9: 520-579; ICD-10: K00-K93 ) 14 24.8 0.6 (0.31 - 0.95)
Diseases of the genitourinary system (ICD-9: 580-629; ICD-10: N00-N99) 3 4.9 0.6 (0.12 - 1.78)
Diseases of the skin and subcutaneous tissue (ICD-9: 680-709; ICD-10: L00-L99) 2 0.4 5.3 (0.59 - 18.98)
Diseases of the musculoskeletal system and connective tissue (ICD-9:710-739; ICD-10: M00-M99) 5 1.8 2.7 (0.88 - 6.34)
Congenital anomalies, excluding neurofibromatosis (ICD-9:740-759;
ICD-10: Q00-Q99, excluding Q85.0)
3 3.6 0.8 (0.17 - 2.44)
Injury and poisoning (ICD-9: 800-999; ICD-10: S00-T98) 11 83.6 0.1 (0.07 - 0.24)
TOTAL 531
Italy, 1995-2003 and 2006.
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viduals with and without NF1 being mostly due to pre-
mature mortality from NF1 or NF1-associated causes.
However, the finding that there was still a gap of
10 years when considering persons who died at 40 years
of age or older suggests that NF1-associated disorders
increase the risk of premature mortality also later in life.
As expected, among males, mortality was higher, though
not significantly, and the mean age at death was signifi-
cantly lower. However, the gender difference in age at
death was smaller among persons with NF1 (4.4 years)
compared to the general population (6.7 years), suggesting
that women are affected by more severe NF1-related com-
plications or that NF1 is more likely to be reported on the
death certificates of young women. Some studies have
shown that women with NF1 have a higher risk of malig-
nancies than males [17,18], though others have not
[2,19,20]. However, during pregnancy and puberty, the
progression to malignancy and the number and size of
neurofibromas may increase in women with NF1 [21], and
the greater attention placed on the health of women dur-
ing pregnancy or childbearing could be reflected in a
greater tendency for NF1 to be reported on the death
certificates of young women.
The comparison of the two calendar periods may sug-
gest that the survival of persons with NF1 has slightly
increased, though longer time series need to be evaluated.
For the leading causes of NF1-associated deaths, we
found an excess for malignant neoplasms of connective
and other soft tissue and brain, which is not surprising.
In fact, NF1 is unlikely to cause death, which is usually
caused by NF1-related complications, mainly tumors of
the peripheral or central nerve tissue [4-6,9,11,22-28]. In
particular, optic gliomas and cutaneous, subcutaneous
and plexiform neurofibromas, which are diagnostic of
NF1, can become malignant or they can remain benign
yet cause pressure on the spinal cord or stenosis and
occlusion of cerebral arteries. We also found a significant
excess, though smaller or for very few cases, for neo-
plasm of unspecified parts of the nervous system,
neoplasm of ill-defined/unspecified sites, and neoplasm
of unspecified nature; when we reviewed these death cer-
tificates, we found that all of them mentioned involve-
ment of the brain or nervous system; it is thus likely that
the PMRs for malignant neoplasm of brain and connec-
tive and soft tissue were underestimated. Moreover, of
the 150 deaths with neurofibromatosis recorded as the
underlying cause, 17 mentioned lethal complications, and
Table 4 NF1-associated deaths by selected underlying cause, stratified by age
People died at age < 40 years
Number
Underlying cause of death (ICD-9 and ICD-10 Codes ) Observ. Expect. PMRs 95% CI
Neurofibromatosis (ICD-9: 237.7; ICD-10: Q85.0) 59 -
Neoplasms, excluding neurofibromatosis (ICD-9: 140-239, excluding 237.7; ICD-10: C00-D48) 77 26.1 2.9 (2.33 - 3.68)
Malignant Neoplasms (ICD-9: 140-208; ICD-10: C00-C97) 68 24.6 2.8 (2.15 - 3.51)
Connective and other soft tissue (ICD-9:171; ICD-10: C49) 21 0.9 23.4 (14.45 - 35.71)
Brain (ICD-9:191; ICD-10: C71) 19 2.5 7.5 (4.50 - 11.67)
Other and unspecified parts of nervous system (ICD-9:192; ICD-10: C70; C72) 3 0.1 32.7 (6.58 - 95.68)
Neoplasm without specification of site (ICD-9:199; ICD-10: C80) 4 0.6 6.8 (1.82 - 17.37)
Benign Neoplasms (ICD-9:210-229; ICD-10: D10-D36) 2 0.2 11.0 (1.23 - 39.54)
Neoplasms of uncertain behavior and unspecified nature, excluding
neurofibromatosis (ICD-9: 235-239, excluding 237.7; ICD-10: D37-D48)
7 1.4 5.1 (2.04 - 10.50)
TOTAL 151
People died at age ≥ 40 years
Number
Underlying cause of death (ICD-9 and ICD-10 Codes ) Observ. Expect. PMRs 95% CI
Neurofibromatosis (ICD-9: 237.7; ICD-10: Q85.0) 91 -
Connective and other soft tissue (ICD-9:171; ICD-10: C49) 14 0.7 20.8 (11.35 - 34.87)
Benign Neoplasms (ICD-9:210-229; ICD-10: D10-D36) 5 0.6 8.7 (2.79 - 20.22)
Neoplasms of uncertain behavior and unspecified nature, excluding
neurofibromatosis (ICD-9: 235-239, excluding 237.7; ICD-10: D37-D48)
10 4.4 2.3 (1.09 - 4.19)
Diseases of the respiratory system (ICD-9: 460-519; ICD-10: J00-J99) 30 18.2 1.6 (1.11 - 2.35)
Obstructive chronic bronchitis (ICD-9: 491.2; ICD-10: J44.8) 13 6.4 2.0 (1.08 - 3.47)
Diseases of the musculoskeletal system and connective tissue (ICD-9:710-739; ICD-10: M00-M99) 5 1.4 3.6 (1.15 - 8.34)
TOTAL 380
Italy, 1995-2003 and 2006.
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of brain and connective soft tissue, they were not listed as
the underlying cause. The decision as to what should be
listed as the underlying cause could reflect differences in
how individual physicians interpret the hierarchy of
causes of death.
The estimated PMRs stratified by age confirmed the
weight of premature mortality in NF1-associated deaths
due to cancer.
With regard to non-neoplastic diseases, the 2-fold excess
for obstructive chronic bronchitis among persons 40 years
of age and older is consistent with the well-known respira-
tory manifestations of NF1. In NF1, the thorax and lungs
can be affected in several ways, given the dense distribu-
tion of peripheral nerves throughout the thorax: cutaneous
and subcutaneous neurofibromas on the chest wall and
chest wall deformities; kyphoscoliosis; ribbon deformity of
the ribs; thoracic neoplasms; parenchymal neurogenetic
tumors [29-31]; and other respiratory manifestations that
severely impair pulmonary function, such as upper airway
obstruction by neurofibromas, central hypoventilation,
diaphragm paralysis, diffuse and interstitial lung disease,
and primary pulmonary hypertension [32-35].
The findings of the present study are consistent with
those of the only other nationally representative popula-
tion-based study on NF1 mortality using death certifi-
cates, which was conducted by Rasmussen et al. [12], as
well as those of smaller survival studies based on the clin-
ical follow-up of persons with NF1, performed in other
industrialized countries [36]. In particular, the study
by Rasmussen et al. [12], whose methodology was very
similar to ours, found a mean annual frequency of NF1-
associated deaths of 1/8 700 deaths for the period 1983-
1997, which is slightly higher than our estimate of 1/10
685 deaths for a later period, 1995-2006. However, this
difference could reflect temporal changes in the mortality
of the general population rather than true differences in
the survival of the NF1-population. In fact, Rasmussen
found a mean age at death of White persons with NF1 of
55.4 years, which is very similar to our estimate of 55.5
years. Furthermore, in both studies, the difference in age
at death between men and women was smaller among
persons with NF1 compared to the general population.
Moreover, the two studies show similar patterns of
excesses/deficits for all conditions likely to be an underly-
ing cause (i.e., malignant neoplasms of connective and
soft tissue and brain). By contrast, the results differed
with regard to other conditions (i.e., curvature of spine,
epilepsy and mental retardation), which could be because
Rasmussen analyzed all diagnoses reported on the death
certificate, whereas we analyzed only the underlying
cause.
Some potential limitations of this study need to be
considered. Regarding the exclusion of NF1-associated
deaths, we are quite confident that any bias would be
negligible because the diagnoses were written out (as
opposed to being coded), which allowed us to select
nearly all death certificates with a diagnosis of NF1 and
d i s t i n g u i s hi tf r o mN F 2 .W es e a r c h e df o rt h et e r m s
“neurofibromatosis”, “Von Recklinghausen disease”,a n d
specific symptoms, including synonyms, acronyms and
short forms. Thus the only death certificates potentially
excluded were those with a diagnosis entered so incor-
rectly that it eluded the dictionary of medical terms
used by ISTAT. Regarding the erroneous inclusion of
NF2 cases, as mentioned, NF1 and NF2 can be distin-
guished because the diagnoses are written out; they
can also be distinguished when a diagnosis of neurofi-
bromatosis with no other specification is reported yet
the diagnoses of some complications/symptoms specific
to NF1 or NF2 are reported. Although it is possible that
the 215 cases with a diagnosis of neurofibromatosis
without either specification or specific complications/
symptoms included some cases of NF2, the mean age at
death of these cases did not significantly differ from that
of the other 418 cases with NF1, whereas the 23 cases
excluded because of an evident or probable diagnosis of
NF2 were significantly younger than the selected cases,
which is consistent with the greater severity for NF2.
Multiple-Causes-of-Death records were missing for the
provinces of Trento and Bolzano, yet given that only 3
persons with neurofibromatosis were identified based
on the National Mortality Database, this probably did
not affect our results. Finally, the quality of data
must be considered. Although the automated selection
of the underlying cause of death has reduced coding
and processing errors [37], the completeness and accu-
racy of the death certificate and the decedent’s medical
diagnosis remain as potential sources of error [38,39].
Because physicians report only those conditions and co-
morbidities that they believe (or know) to have been
instrumental in causing deat h ,i ti sl i k e l yt h a ts t u d i e s
based on death certificates detect only severe NF1-cases,
resulting in a potential underestimate of the life expec-
tancy of persons with NF1. It is also likely that only
associations with conditions well-known to be associated
with NF1 were revealed, resulting in a potentially biased
pattern of excesses/deficits for other clinical conditions.
Furthermore, the PMR is probably underestimated for
conditions that are frequent among NF1 patients and
known to be associated with the disease, such as breast
cancer, nervous system diseases, and hypertensive dis-
ease. This is because these diseases are unlikely to be
considered as the underlying cause or to be directly
involved in causing death when more aggressive compli-
cations are present, and in our study, to study the asso-
ciation between NF1 and other conditions, we were able
Masocco et al. Orphanet Journal of Rare Diseases 2011, 6:11
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coded cause reported on death certificates).
Finally, death certificates do not allow all persons with
NF1 to be identified; thus the association with other
conditions should not be interpreted as the risk of
developing that condition among living persons with
NF1.
Conclusion
Despite the limits discussed above, this study has impor-
tant strengths. To the best of our knowledge, it is the
first nationally representative population-based study on
NF1-associated mortality in Italy. The combined use of
the two national data sources allows for comparison with
data from the general population and reveals the useful-
ness of already available data when a surveillance system
is not fully operational. This study also stresses the
importance of the Multiple-Causes-of-Death Database in
providing a more complete picture of mortality for con-
ditions that are frequently not recorded as the underlying
cause of death, or to study complex chronic diseases or
diseases that have no specific ICD code, such as NF1.
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